Darling Ingredients (DAR) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
Q2 2024 net sales were $1.46 billion, down 17% year-over-year, with net income at $78.9 million, a 69% decrease, mainly due to lower commodity prices and reduced DGD Joint Venture earnings.
Combined adjusted EBITDA for Q2 2024 was $273.6 million, down from $508.3 million in Q2 2023.
Share repurchase activity totaled $29.2 million in Q2, with the program extended to August 2026 and $500 million authorized.
Specialty ingredients and core business margins improved sequentially, while DGD had a solid quarter despite Port Arthur downtime.
Focus for the remainder of 2024 is on debt reduction, margin expansion, and operational initiatives.
Financial highlights
Q2 2024 net income was $78.9 million ($0.49 per diluted share), down from $252.4 million ($1.55 per share) in Q2 2023.
Net sales for Q2 2024 were $1.46 billion, compared to $1.8 billion in Q2 2023.
Operating income for Q2 2024 was $148.5 million, down $208.2 million year-over-year, mainly due to a $168.8 million decline in DGD equity income.
Gross margin for Q2 2024 was 22.5%, nearly flat in percentage but down 17.8% in dollars year-over-year.
For the first six months, net income was $160 million ($0.99 per share) vs. $438.2 million ($2.69 per share) in 2023; net sales were $2.88 billion vs. $3.5 billion.
Outlook and guidance
Management reaffirmed full-year adjusted EBITDA guidance of $1.3–$1.4 billion, expecting stronger Q4 than Q3 as fat prices rebound.
No earnings from SAF included in guidance; any contribution would be incremental.
Focus remains on operational excellence, margin management, and continued DGD dividends.
Latest events from Darling Ingredients
- All director nominees, auditor ratification, and key compensation plans were approved.DAR
AGM 202614 May 2026 - Accelerated growth, strong cash flow, and innovation in collagen set the stage for robust expansion.DAR
21st Annual Global Farm to Market Conference13 May 2026 - Global scale, strong cash flow, and innovation in renewables and collagen drive profitable growth.DAR
Investor Day 202611 May 2026 - Net income hit $134.3 million and Adjusted EBITDA more than doubled year-over-year.DAR
Q1 20268 May 2026 - Q4/FY2025 sales and margins rose, but net income fell sharply on restructuring charges.DAR
Q4 202512 Apr 2026 - Shareholders will vote on directors, auditor, executive pay, and a new incentive plan amid strong 2025 results.DAR
Proxy filing19 Mar 2026 - Virtual annual meeting to vote on directors, auditor, compensation, and incentive plan.DAR
Proxy filing19 Mar 2026 - Global leader in animal byproduct repurposing, poised for growth in food, feed, and renewables.DAR
47th Annual Raymond James Institutional Investor Conference2 Mar 2026 - Bullish 2026 outlook with policy clarity, JV expansion, and strong growth in renewables and collagen.DAR
Jefferies Renewables & Clean Energy Conference22 Jan 2026